What is included in the long-term monitoring of organ transplantation-related osteoporosis?

Updated: Jul 02, 2020
  • Author: Carmel M Fratianni, MD, FACE; Chief Editor: George T Griffing, MD  more...
  • Print


In the transplant recipient, annual assessments of BMD by DEXA scanning are prudent. Any clinical suggestion of fracture should prompt bone radiographs.

If an antiresorptive agent such as alendronate is used, significant increases in spine BMD may be observed within 1 year. An increase in femoral neck BMD may not be seen until after an average of 4-5 years of treatment with alendronate or risedronate, and probably longer with weaker antiresorptive agents.

Renal transplant recipients represent an unusual population. Bone biopsy may occasionally be required to evaluate for the possibility of adynamic bone disease prior to bisphosphonate therapy. [69]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!